Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorios Farmaceuticos RoviLABFF 89 Price-to-Tangible-Book is 6.28 as of Jul. 22, 2026, which is 26% above its 10-year median of 4.97. GuruFocus rates LABFF with a GF Score™ of 89/100 and a GF Value™ of $85.32. The stock has 1 warning sign investors should review. Among 836 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks worse than 74.88% on this metric.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Price-to-Tangible-Book or its related term are showing as below:
LABFF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.79 Med: 4.97 Max: 10.11
Current: 4.34
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest Price to Tangible Book Ratio was 10.11. The lowest was 3.79. And the median was 4.97.
LABFF's Price-to-Tangible-Book is ranked worse than 74.88% of 836
companies
in the Drug Manufacturers industry
Industry Median: 2.185
vs LABFF: 4.34
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Laboratorios Farmaceuticos Rovi Price-to-Tangible-Book Related Terms
Laboratorios Farmaceuticos Rovi Price-to-Tangible-Book Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LABFF vs ZTS, UTHR, VTRS: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Laboratorios Farmaceuticos Rovi (LABFF) has a Price-to-Tangible-Book of 6.28 as of Jul. 22, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 26% above median its historical median of 4.97. Over the past decade, Laboratorios Farmaceuticos Rovi's Price-to-Tangible-Book has ranged from 3.79 to 10.11. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #626 out of 836 companies in the Drug Manufacturers industry, placing it in the top 74.9%.
Is Laboratorios Farmaceuticos Rovi's Price-to-Tangible-Book too high?
Laboratorios Farmaceuticos Rovi's current Price-to-Tangible-Book of 6.28 is 26% above median its 10-year median of 4.97. Over the past 10 years, this metric has ranged from a low of 3.79 to a high of 10.11. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.19. Laboratorios Farmaceuticos Rovi's value of 6.28 is 187.4% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #626 out of 836 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Price-to-Tangible-Book compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #626 out of 836 companies for Price-to-Tangible-Book. This places Laboratorios Farmaceuticos Rovi in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.19. Laboratorios Farmaceuticos Rovi's value of 6.28 is 187.4% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Price-to-Tangible-Book has ranged from 3.79 to 10.11 over the past decade. While the company's 10-year median is 4.97 vs. the industry median of 2.19, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.19, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Price-to-Tangible-Book of 6.28 is 187.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Price-to-Tangible-Book is 6.28, which is 26% above median its own 10-year median of 4.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Price-to-Tangible-Book of 6.28. The stock's GF Value™ is $85.32, compared to a current price of $90.61 — trading 6.2% above its estimated fair value. The current Price-to-Tangible-Book is 6.28, which is 26% above median its 10-year median of 4.97 and 187.4% above the Drug Manufacturers industry median of 2.19. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Price-to-Tangible-Book is 6.28 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 6.2% above its estimated GF Value™ of $85.32.
Key valuation signals for LABFF:
Price-to-Tangible-Book: 6.28 (26% above median its 10-year median of 4.97)
GF Value™: $85.32 vs. price of $90.61 (6.2% above fair value)
Industry Position: 187.4% above the Drug Manufacturers median (#626 of 836)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
89GF Score
Get the complete analysis for LABFF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
